FASLG and antiphospholipid syndrome: Finally, in patients with anti-phospholipid syndrome (APS), circulating aPL (anti-phospholipid) antibodies disrupt the anticoagulant crystallization shied of anxA5 and consequently highly promote thrombosis in the placenta and the cardiovascular system [64–67].